| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10.36M | 25.17M | 17.55M | 10.59M | 42.12M | 828K | 43K | 26.58M | 36.85M | 40.5M |
| Revenue Growth % | - | 1.43% | -0.3% | -0.4% | 2.98% | -0.98% | -0.95% | 617.16% | 0.39% | 0.1% |
| Cost of Goods Sold | 21.35M | 32.01M | 928K | 59.91M | 0 | 67.04M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 2.06% | 1.27% | 0.05% | 5.66% | - | 80.96% | - | - | - | - |
| Gross Profit | -10.99M | -6.84M | 16.62M | -49.32M | 42.12M | -66.21M | 43K | 26.58M | 36.85M | 40.5M |
| Gross Margin % | -1.06% | -0.27% | 0.95% | -4.66% | 1% | -79.96% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 0.38% | 3.43% | -3.97% | 1.85% | -2.57% | 1% | 617.16% | 0.39% | 0.1% |
| Operating Expenses | 26.7M | 38.99M | 57.16M | 76.25M | 72.32M | 88.94M | 168.9M | 230.35M | 207.81M | 113.83M |
| OpEx % of Revenue | 2.58% | 1.55% | 3.26% | 7.2% | 1.72% | 107.41% | 3927.93% | 8.67% | 5.64% | 2.81% |
| Selling, General & Admin | 5.35M | 6.98M | 10.46M | 16.33M | 17.28M | 21.9M | 36.89M | 56.96M | 59.54M | 40.81M |
| SG&A % of Revenue | 0.52% | 0.28% | 0.6% | 1.54% | 0.41% | 26.45% | 857.86% | 2.14% | 1.62% | 1.01% |
| Research & Development | 21.35M | 32.01M | 46.7M | 59.91M | 55.04M | 67.04M | 132.01M | 173.38M | 148.27M | 73.02M |
| R&D % of Revenue | 2.06% | 1.27% | 2.66% | 5.66% | 1.31% | 80.96% | 3070.07% | 6.52% | 4.02% | 1.8% |
| Other Operating Expenses | -89K | 0 | 0 | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.34M | -13.82M | -39.62M | -65.66M | -30.2M | -155.15M | -168.86M | -203.77M | -170.96M | -73.34M |
| Operating Margin % | -1.58% | -0.55% | -2.26% | -6.2% | -0.72% | -187.37% | -3926.93% | -7.67% | -4.64% | -1.81% |
| Operating Income Growth % | - | 0.15% | -1.87% | -0.66% | 0.54% | -4.14% | -0.09% | -0.21% | 0.16% | 0.57% |
| EBITDA | -16.04M | -13.17M | -38.69M | -64.4M | -28.95M | -154.14M | -168M | -202.84M | -169.44M | -71.71M |
| EBITDA Margin % | -1.55% | -0.52% | -2.21% | -6.08% | -0.69% | -186.15% | -3907.05% | -7.63% | -4.6% | -1.77% |
| EBITDA Growth % | - | 0.18% | -1.94% | -0.66% | 0.55% | -4.32% | -0.09% | -0.21% | 0.16% | 0.58% |
| D&A (Non-Cash Add-back) | 297K | 655K | 928K | 1.26M | 1.25M | 1.01M | 855K | 927K | 1.52M | 1.63M |
| EBIT | -16.34M | -13.82M | -38.71M | -64.26M | -27.97M | -88.11M | -168.79M | -200.88M | -167.6M | -64.9M |
| Net Interest Income | 2K | 121K | 910K | 1.4M | 1.99M | 65K | -1.2M | -445K | 8M | 4.56M |
| Interest Income | 2K | 121K | 910K | 1.4M | 2.23M | 424K | 65K | 2.88M | 12.07M | 8.44M |
| Interest Expense | 0 | 0 | 0 | 0 | 234K | 359K | 1.27M | 3.33M | 4.07M | 3.87M |
| Other Income/Expense | -87K | 121K | 910K | 1.4M | 1.99M | 67.1M | -1.2M | -445K | -713K | 4.56M |
| Pretax Income | -16.43M | -13.7M | -38.71M | -64.26M | -28.21M | -88.05M | -170.06M | -204.21M | -171.67M | -68.77M |
| Pretax Margin % | -1.59% | -0.54% | -2.21% | -6.07% | -0.67% | -106.33% | -3954.88% | -7.68% | -4.66% | -1.7% |
| Income Tax | -2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1.01% |
| Net Income | -16.43M | -13.7M | -38.71M | -64.26M | -28.21M | -88.05M | -170.06M | -204.21M | -171.67M | -69.19M |
| Net Margin % | -1.59% | -0.54% | -2.21% | -6.07% | -0.67% | -106.33% | -3954.88% | -7.68% | -4.66% | -1.71% |
| Net Income Growth % | - | 0.17% | -1.83% | -0.66% | 0.56% | -2.12% | -0.93% | -0.2% | 0.16% | 0.6% |
| Net Income (Continuing) | -16.43M | -13.7M | -38.71M | -64.26M | -28.21M | -88.05M | -170.06M | -204.21M | -171.67M | -69.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -23.48 | -19.58 | -42.95 | -69.75 | -16.21 | -35.80 | -60.24 | -54.51 | -36.96 | -14.12 |
| EPS Growth % | - | 0.17% | -1.19% | -0.62% | 0.77% | -1.21% | -0.68% | 0.1% | 0.32% | 0.62% |
| EPS (Basic) | -23.48 | -19.58 | -43.00 | -69.75 | -16.25 | -35.80 | -60.24 | -54.51 | -36.96 | -14.12 |
| Diluted Shares Outstanding | 699.73K | 699.73K | 901.17K | 921.29K | 1.74M | 2.46M | 2.82M | 3.75M | 4.64M | 4.9M |
| Basic Shares Outstanding | 699.73K | 699.73K | 900.14K | 921.29K | 1.74M | 2.46M | 2.82M | 3.75M | 4.64M | 4.9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 12.75M | 102.17M | 117.54M | 70.13M | 101.33M | 258.58M | 188.9M | 319.22M | 214.06M | 136.9M |
| Cash & Short-Term Investments | 11.53M | 100.3M | 114.73M | 70.13M | 99.79M | 255.09M | 177.95M | 280.71M | 209.08M | 134.62M |
| Cash Only | 11.53M | 100.3M | 26.59M | 59.63M | 62.35M | 255.09M | 177.95M | 128.88M | 174.56M | 107.75M |
| Short-Term Investments | 0 | 0 | 88.14M | 10.5M | 37.44M | 0 | 0 | 151.83M | 34.52M | 26.87M |
| Accounts Receivable | 640K | 1.05M | 784K | 459K | 0 | 0 | 0 | 30M | 0 | 0 |
| Days Sales Outstanding | 22.55 | 15.24 | 16.31 | 15.81 | - | - | - | 411.95 | - | - |
| Inventory | 0 | 0 | 0 | -4.17M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 2.02M | 3.71M | 1.54M | 0 | 10.95M | 8.51M | 4.97M | 2.28M |
| Total Non-Current Assets | 1.66M | 2.91M | 13.17M | 8.37M | 6.21M | 14.82M | 17.21M | 15.12M | 12M | 7.76M |
| Property, Plant & Equipment | 1.28M | 2.48M | 2.32M | 2.69M | 4.76M | 12.67M | 14.86M | 14.46M | 11.53M | 6.78M |
| Fixed Asset Turnover | 8.07x | 10.14x | 7.57x | 3.93x | 8.85x | 0.07x | 0.00x | 1.84x | 3.20x | 5.97x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 321K | 10.48M | 371K | 321K | 321 | 478K | 0 | 0 | 0 |
| Other Non-Current Assets | 371K | 110K | 371K | 5.31M | 1.13M | 2.15M | 1.88M | 661K | 478K | 978K |
| Total Assets | 14.41M | 105.09M | 130.72M | 78.5M | 107.54M | 273.4M | 206.11M | 334.34M | 226.06M | 144.66M |
| Asset Turnover | 0.72x | 0.24x | 0.13x | 0.13x | 0.39x | 0.00x | 0.00x | 0.08x | 0.16x | 0.28x |
| Asset Growth % | - | 6.29% | 0.24% | -0.4% | 0.37% | 1.54% | -0.25% | 0.62% | -0.32% | -0.36% |
| Total Current Liabilities | 10.73M | 28.39M | 31.88M | 69.42M | 24.07M | 30M | 47.52M | 91.53M | 63.64M | 62.46M |
| Accounts Payable | 2.02M | 2.07M | 3.07M | 10.73M | 7.3M | 8.34M | 12.32M | 13.95M | 7.32M | 4.33M |
| Days Payables Outstanding | 34.61 | 23.58 | 1.21K | 65.35 | - | 45.41 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 667K | 93K | 0 | 0 | 2.08M | 12.5M |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 0 | 1.31M | 4.13M | 9.46M | 5.04M | 10.83M | 21.64M | 990K | 13.88M | 12.26M |
| Current Ratio | 1.19x | 3.60x | 3.69x | 1.01x | 4.21x | 8.62x | 3.97x | 3.49x | 3.36x | 2.19x |
| Quick Ratio | 1.19x | 3.60x | 3.69x | 1.07x | 4.21x | 8.62x | 3.97x | 3.49x | 3.36x | 2.19x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 46.37M | 132.32M | 28.84M | 282K | 5.15M | 15.31M | 36.85M | 150.75M | 125.52M | 91.71M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 4.2M | 4.98M | 24.63M | 24.93M | 23.15M | 10.95M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 677K | 10.16M | 11.25M | 8.57M | 5.2M | 1.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 36.3M | 94.75M | 67K | 282K | 275K | 174K | 974K | 203K | 1K | 8K |
| Total Liabilities | 57.1M | 160.71M | 60.72M | 69.71M | 29.22M | 45.31M | 84.37M | 242.28M | 189.16M | 154.17M |
| Total Debt | 0 | 0 | 0 | 0 | 7.76M | 16.66M | 38.18M | 36.3M | 33.83M | 28.6M |
| Net Debt | -11.53M | -100.3M | -26.59M | -59.63M | -54.59M | -238.43M | -139.77M | -92.58M | -140.73M | -79.15M |
| Debt / Equity | - | - | - | - | 0.10x | 0.07x | 0.31x | 0.39x | 0.92x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -129.06x | -432.16x | -133.27x | -61.23x | -41.97x | -18.93x |
| Total Equity | -42.69M | -55.62M | 69.99M | 8.79M | 78.32M | 228.09M | 121.74M | 92.06M | 36.9M | -9.51M |
| Equity Growth % | - | -0.3% | 2.26% | -0.87% | 7.9% | 1.91% | -0.47% | -0.24% | -0.6% | -1.26% |
| Book Value per Share | -61.01 | -79.49 | 77.67 | 9.55 | 45.02 | 92.74 | 43.12 | 24.57 | 7.95 | -1.94 |
| Total Shareholders' Equity | -42.69M | -55.62M | 69.99M | 8.79M | 78.32M | 228.09M | 121.74M | 92.06M | 36.9M | -9.51M |
| Common Stock | 1K | 1K | 3K | 3K | 5K | 7K | 7K | 11K | 12K | 12K |
| Retained Earnings | -45.47M | -59.17M | -97.88M | -164.17M | -192.37M | -280.42M | -450.48M | -654.69M | -826.36M | -895.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3.56M | -4.21M | -149K | -8K | 25K | 0 | 0 | -152K | 11K | 10K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.64M | 31.59M | -42.68M | -55.22M | -67.74M | -74.7M | -139.99M | -49.36M | -168.88M | -82.34M |
| Operating CF Margin % | -0.93% | 1.25% | -2.43% | -5.21% | -1.61% | -90.21% | -3255.53% | -1.86% | -4.58% | -2.03% |
| Operating CF Growth % | - | 4.28% | -2.35% | -0.29% | -0.23% | -0.1% | -0.87% | 0.65% | -2.42% | 0.51% |
| Net Income | -16.43M | -13.7M | -38.71M | -64.26M | -28.21M | -88.05M | -170.06M | -204.21M | -171.67M | -69.19M |
| Depreciation & Amortization | 297K | 655K | 928K | 1.26M | 1.25M | 1.01M | 855K | 927K | 1.52M | 1.63M |
| Stock-Based Compensation | 349K | 668K | 1.42M | 3.88M | 4.87M | 7.17M | 18.41M | 21.52M | 21.14M | 16.46M |
| Deferred Taxes | -349K | -102K | -134K | -386K | -222K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 349K | 102K | -159K | 110K | 103K | 62K | 723K | -699K | -1.1M | -496K |
| Working Capital Changes | 6.15M | 43.97M | -6.03M | 4.18M | -45.53M | 5.11M | 10.09M | 133.1M | -18.76M | -30.74M |
| Change in Receivables | 1.2M | -411K | 267K | 325K | 459K | 0 | 0 | -30M | 30M | 0 |
| Change in Inventory | 304K | 1.42M | 2.42M | 2.61M | -1.5M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 926K | -325K | 1.33M | 7.38M | -3.11M | 942K | 483K | 947K | -6.08M | -2.86M |
| Cash from Investing | -783K | -1.08M | -99.62M | 87.19M | -27.29M | 37.03M | -648K | -152.72M | 119.88M | 11.44M |
| Capital Expenditures | -619K | -1.08M | -1.14M | -1.37M | -605K | -473K | -648K | -2.2M | -2.17M | -132K |
| CapEx % of Revenue | 0.06% | 0.04% | 0.07% | 0.13% | 0.01% | 0.57% | 15.07% | 0.08% | 0.06% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -164K | 0 | -98.48M | 88.56M | -26.69M | 0 | 0 | -150.52M | 0 | 0 |
| Cash from Financing | 9.96M | 58.26M | 68.6M | 1.06M | 97.7M | 230.41M | 63.65M | 153.02M | 94.67M | 4.09M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 105K | 452K | 1.06M | 664K | 3.7M | 2.22M | 2.4M | 1.4M | 542K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -10.26M | 30.5M | -43.82M | -56.59M | -68.35M | -75.17M | -140.64M | -51.56M | -171.05M | -82.47M |
| FCF Margin % | -0.99% | 1.21% | -2.5% | -5.34% | -1.62% | -90.78% | -3270.6% | -1.94% | -4.64% | -2.04% |
| FCF Growth % | - | 3.97% | -2.44% | -0.29% | -0.21% | -0.1% | -0.87% | 0.63% | -2.32% | 0.52% |
| FCF per Share | -14.66 | 43.59 | -48.63 | -61.42 | -39.29 | -30.56 | -49.81 | -13.76 | -36.83 | -16.83 |
| FCF Conversion (FCF/Net Income) | 0.59x | -2.31x | 1.10x | 0.86x | 2.40x | 0.85x | 0.82x | 0.24x | 0.98x | 1.19x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 234K | 0 | 0 | 0 | 3.47M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -538.53% | -163.11% | -64.76% | -57.47% | -97.22% | -191.03% | -266.24% | -505.14% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -1738.14% | - | - | - | - |
| Gross Margin | -106.13% | -27.16% | 94.71% | -465.56% | 100% | -7996.14% | 100% | 100% | 100% | 100% |
| Net Margin | -158.59% | -54.43% | -220.62% | -606.54% | -66.97% | -10633.45% | -395488.37% | -768.26% | -465.8% | -170.86% |
| Debt / Equity | - | - | - | - | 0.10x | 0.07x | 0.31x | 0.39x | 0.92x | - |
| Interest Coverage | - | - | - | - | -129.06x | -432.16x | -133.27x | -61.23x | -41.97x | -18.93x |
| FCF Conversion | 0.59x | -2.31x | 1.10x | 0.86x | 2.40x | 0.85x | 0.82x | 0.24x | 0.98x | 1.19x |
| Revenue Growth | - | 142.99% | -30.3% | -39.62% | 297.61% | -98.03% | -94.81% | 61716.28% | 38.65% | 9.88% |
Mersana Therapeutics, Inc. (MRSN) reported $33.2M in revenue for fiscal year 2024. This represents a 220% increase from $10.4M in 2015.
Mersana Therapeutics, Inc. (MRSN) grew revenue by 9.9% over the past year. This is steady growth.
Mersana Therapeutics, Inc. (MRSN) reported a net loss of $70.1M for fiscal year 2024.
Mersana Therapeutics, Inc. (MRSN) has a return on equity (ROE) of -505.1%. Negative ROE indicates the company is unprofitable.
Mersana Therapeutics, Inc. (MRSN) had negative free cash flow of $74.4M in fiscal year 2024, likely due to heavy capital investments.